MX377093B - Formulaciones de apolipoproteína de dosificación fija. - Google Patents
Formulaciones de apolipoproteína de dosificación fija.Info
- Publication number
- MX377093B MX377093B MX2014006589A MX2014006589A MX377093B MX 377093 B MX377093 B MX 377093B MX 2014006589 A MX2014006589 A MX 2014006589A MX 2014006589 A MX2014006589 A MX 2014006589A MX 377093 B MX377093 B MX 377093B
- Authority
- MX
- Mexico
- Prior art keywords
- fixed dosage
- formulation
- apolipoprotein formulation
- apolipoprotein
- dosage apolipoprotein
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 102000007592 Apolipoproteins Human genes 0.000 title abstract 4
- 108010071619 Apolipoproteins Proteins 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 abstract 4
- 208000004476 Acute Coronary Syndrome Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 102000015779 HDL Lipoproteins Human genes 0.000 abstract 1
- 108010010234 HDL Lipoproteins Proteins 0.000 abstract 1
- 208000007814 Unstable Angina Diseases 0.000 abstract 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 abstract 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 abstract 1
- 229940099352 cholate Drugs 0.000 abstract 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 abstract 1
- 239000003599 detergent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 231100000304 hepatotoxicity Toxicity 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 230000007056 liver toxicity Effects 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- -1 phosphatidylcholine Chemical class 0.000 abstract 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Marine Sciences & Fisheries (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2011905368A AU2011905368A0 (en) | 2011-12-21 | Dosing regime for apolipoprotein formulations | |
| PCT/AU2012/001345 WO2013090978A1 (en) | 2011-12-21 | 2012-11-02 | Dosage regime for apolipoprotein formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014006589A MX2014006589A (es) | 2014-10-17 |
| MX377093B true MX377093B (es) | 2025-03-07 |
Family
ID=48667485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014006589A MX377093B (es) | 2011-12-21 | 2012-11-02 | Formulaciones de apolipoproteína de dosificación fija. |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20140378376A1 (https=) |
| EP (1) | EP2793913B1 (https=) |
| JP (2) | JP6144276B2 (https=) |
| KR (3) | KR20190084334A (https=) |
| CN (2) | CN113398245A (https=) |
| AU (1) | AU2012310259C1 (https=) |
| BR (1) | BR112014014403A8 (https=) |
| CA (1) | CA2857968A1 (https=) |
| DK (1) | DK2793913T3 (https=) |
| ES (1) | ES2955110T3 (https=) |
| IL (1) | IL233236A0 (https=) |
| MX (1) | MX377093B (https=) |
| PL (1) | PL2793913T3 (https=) |
| RU (1) | RU2014129505A (https=) |
| SG (1) | SG11201402556RA (https=) |
| WO (1) | WO2013090978A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9645037B2 (en) | 2011-09-28 | 2017-05-09 | Hunter Engineering Company | Method and apparatus for wheel assembly lateral force measurement |
| PL2793913T3 (pl) * | 2011-12-21 | 2023-11-06 | Csl Limited | Schemat dawkowania dla formulacji apolipoproteiny |
| SG11201903945XA (en) | 2016-11-10 | 2019-05-30 | Csl Ltd | Reconstituted high density lipoprotein treatment of myocardial infarction |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61152632A (ja) * | 1984-12-26 | 1986-07-11 | Dai Ichi Seiyaku Co Ltd | 抗動脈硬化剤 |
| US5652339A (en) | 1993-12-31 | 1997-07-29 | Rotkreuzstiftung Zentrallaboratorium | Method of producing reconstituted lipoproteins |
| EP2343317A1 (en) * | 2000-11-10 | 2011-07-13 | F. Hoffmann-La Roche Ltd. | Apolipoprotein analogues |
| AU2002362612B2 (en) * | 2001-09-28 | 2007-11-15 | Cedars-Sinai Medical Center | Prevention and treatment of restenosis by local administration of drug |
| AU2003239489A1 (en) * | 2002-05-17 | 2003-12-02 | Esperion Therapeutics, Inc. | Method of treating dyslipidemic disorders |
| EP1545576A2 (en) * | 2002-07-30 | 2005-06-29 | Esperion Therapeutics Inc. | Methods of using non-human animal apoliprotein a-i protein |
| PE20050438A1 (es) * | 2003-10-20 | 2005-06-14 | Esperion Therapeutics Inc | Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos |
| AP2006003578A0 (en) * | 2003-10-20 | 2006-04-30 | Esperion Therapeutics Inc | Pharmaceutical formulations, methods and dosing regimens for the treatment and prevention of acute coronary syndromes. |
| AU2006282722A1 (en) * | 2005-08-26 | 2007-03-01 | Cerenis Therapeutics Holdings S.A. | Compositions and methods for producing apolipoprotein gene products in lactic acid bacteria |
| US20090297577A1 (en) * | 2008-06-02 | 2009-12-03 | Medtronic Vascular, Inc. | Local Delivery of Apolipoproteins and Their Derivatives |
| PL2793913T3 (pl) * | 2011-12-21 | 2023-11-06 | Csl Limited | Schemat dawkowania dla formulacji apolipoproteiny |
-
2012
- 2012-11-02 PL PL12859136.9T patent/PL2793913T3/pl unknown
- 2012-11-02 CN CN202110675512.8A patent/CN113398245A/zh active Pending
- 2012-11-02 JP JP2014547627A patent/JP6144276B2/ja active Active
- 2012-11-02 US US14/364,764 patent/US20140378376A1/en not_active Abandoned
- 2012-11-02 RU RU2014129505A patent/RU2014129505A/ru unknown
- 2012-11-02 AU AU2012310259A patent/AU2012310259C1/en active Active
- 2012-11-02 KR KR1020197019295A patent/KR20190084334A/ko not_active Ceased
- 2012-11-02 DK DK12859136.9T patent/DK2793913T3/da active
- 2012-11-02 WO PCT/AU2012/001345 patent/WO2013090978A1/en not_active Ceased
- 2012-11-02 CN CN201280063210.4A patent/CN104010646A/zh active Pending
- 2012-11-02 KR KR1020207009276A patent/KR102766038B1/ko active Active
- 2012-11-02 MX MX2014006589A patent/MX377093B/es active IP Right Grant
- 2012-11-02 ES ES12859136T patent/ES2955110T3/es active Active
- 2012-11-02 CA CA2857968A patent/CA2857968A1/en not_active Abandoned
- 2012-11-02 KR KR1020147020291A patent/KR20140107536A/ko not_active Ceased
- 2012-11-02 EP EP12859136.9A patent/EP2793913B1/en active Active
- 2012-11-02 BR BR112014014403A patent/BR112014014403A8/pt not_active Application Discontinuation
- 2012-11-02 SG SG11201402556RA patent/SG11201402556RA/en unknown
-
2014
- 2014-06-18 IL IL233236A patent/IL233236A0/en active IP Right Grant
-
2016
- 2016-02-26 US US15/054,358 patent/US20160175392A1/en not_active Abandoned
-
2017
- 2017-03-10 JP JP2017045676A patent/JP2017128586A/ja active Pending
-
2023
- 2023-08-14 US US18/449,039 patent/US20240216467A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123945T1 (el) | Στοματικα σκευασματα αμεσης απελευθερωσης για υποκατεστημενες κιναζολινονες | |
| CY1124499T1 (el) | Λιπιδια για συστασεις διανομης θεραπευτικου παραγοντα | |
| UY29222A1 (es) | Compuestos y derivados de dibencil amina | |
| NZ727849A (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| JOP20160211B1 (ar) | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa | |
| ECSP056040A (es) | 1,2, 4 SUSTITUIDO 1,2,3,4-TETRAHIDRO Y 1,2, DIHIDRO-QUINOLINA y 1,2,3,4-TETRADHIDRO-QUINOXALINA-DERIVADOS COMO INHIBIDORES CETP PARA EL TRATAMIENTO DE ATEROSCLEROSIS Y OBESIDAD | |
| MX383117B (es) | Péptidos miméticos de la apoe y mayor potencia para depurar el colesterol en plasma. | |
| TR201903209T4 (tr) | Yeniden yapılandırılan yüksek yoğunluğa sahip bir lipoprotein formülasyonu ve bunun üretim yöntemi. | |
| MX352328B (es) | Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos. | |
| MX2015012201A (es) | Formulaciones modificadas de liposomas de docetaxel. | |
| MX2015007082A (es) | Métodos de administración de composiciones que comprenden ácido docosapentanoico. | |
| MX377093B (es) | Formulaciones de apolipoproteína de dosificación fija. | |
| EA201490544A1 (ru) | Препараты и лекарственные формы на основе окисленных фосфолипидов | |
| EA201690284A1 (ru) | Композиции и терапевтические способы для ускоренного регресса бляшки | |
| MX2018004637A (es) | Ácidos nucleicos p-etoxi para formulacion liposomal. | |
| NZ631131A (en) | Reconstituted hdl formulation | |
| NI201200070A (es) | Nueva asociación entre la 4 - {3 - [cis -hexahidrociclopenta [c] pirrol - 2 (1h)- il] propoxi} benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmacéuticas que la contienen. | |
| CR9012A (es) | Compuestos de 4-amino-sustituido-2-sustituido-1,2,3,4-tetrahidroquinolina | |
| CY1119064T1 (el) | Ινωδολυτικες συνθεσεις οι οποιες περιεχουν βρωμελαϊνη και ναττοκιναση για την προληψη και αγωγη φλεβοθρομβωτικων καταστασεων | |
| EA200801815A1 (ru) | Дибензиламиносоединения и производные | |
| MX2012007682A (es) | Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso. | |
| JP2015209424A5 (https=) | ||
| UY29124A1 (es) | Compuestos de quinolina | |
| CN302361112S (zh) | 低压动态无功补偿柜（ch-tsc） | |
| CN302055801S (zh) | 电风扇（龙腾） |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |